Silexion Advances SIL204 Toward Phase 2/3 Trials with Strong Preclinical Data
Event summary
- Silexion reported preclinical data showing SIL204's activity across eight KRAS mutations and four cancer types, including first evidence in gastric cancer.
- Completed two-species toxicology studies and received written Scientific Advice from Germany's BfArM for SIL204's Phase 2/3 trial design.
- Submitted Phase 2/3 clinical trial application to Israel's Ministry of Health, with regulatory feedback expected by Q1 2026.
- Raised $18.6 million in 2025, ending the year with $6.0 million in cash and regaining Nasdaq compliance.
- Plans to initiate Phase 2/3 trial in Q2 2026, evaluating SIL204 in combination with standard chemotherapy for locally advanced pancreatic cancer.
The big picture
Silexion's progress with SIL204 underscores the growing focus on KRAS-mutated cancers, a challenging but high-need area in oncology. The company's ability to secure regulatory advice and submit clinical trial applications positions it competitively, though execution risks remain. With $6.0 million in cash, Silexion has a clear runway to advance its lead candidate, but sustained financial discipline will be critical as it navigates the capital-intensive Phase 2/3 trial phase.
What we're watching
- Regulatory Momentum
- Whether Israel and Germany's regulatory feedback will accelerate SIL204's Phase 2/3 trial initiation in 2026.
- Financial Runway
- How Silexion's $6.0 million cash position will support operations until potential future funding rounds.
- Clinical Execution
- The pace at which Silexion can enroll and dose patients in the Phase 2/3 trial, given the planned safety run-in cohort.
Related topics